CG Oncology reports that its bladder cancer immunotherapy, cretostimogene cut, reduces the risk of tumor recurrence by 68% when given after surgery. The results are described as exceptional and are presented as substantially above expectations, with at least one outlet noting an impact on company shares.

Both reports frame the trial outcome as potentially important for clinical practice, suggesting it may influence how doctors treat certain bladder cancer patients in the post-surgery setting. While the endpoints and magnitude of benefit are the focus in both accounts, coverage differs in emphasis: one outlet highlights the strength of the results relative to market expectations and links it to investor reaction, while the other stresses the implications for treatment approaches and physician decision-making.